Your browser is no longer supported. Please, upgrade your browser.
Settings
IMNP Immune Pharmaceuticals, Inc. daily Stock Chart
IMNP [NASD]
Immune Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-14.56 Insider Own0.70% Shs Outstand5.81M Perf Week-14.73%
Market Cap17.49M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month1880.26%
Income-37.10M PEG- EPS next Q- Inst Own3.60% Short Float- Perf Quarter1477.57%
Sales- P/S- EPS this Y38.20% Inst Trans1309.25% Short Ratio3.68 Perf Half Y1527.03%
Book/sh2.12 P/B1.42 EPS next Y- ROA-112.10% Target Price60.00 Perf Year600.00%
Cash/sh0.05 P/C58.29 EPS next 5Y- ROE-508.20% 52W Range0.12 - 5.02 Perf YTD1553.85%
Dividend- P/FCF- EPS past 5Y41.30% ROI- 52W High-40.04% Beta1.90
Dividend %- Quick Ratio0.10 Sales past 5Y- Gross Margin- 52W Low2359.15% ATR0.38
Employees12 Current Ratio0.10 Sales Q/Q- Oper. Margin- RSI (14)71.98 Volatility11.84% 13.71%
OptionableNo Debt/Eq0.31 EPS Q/Q54.80% Profit Margin- Rel Volume0.05 Prev Close2.98
ShortableNo LT Debt/Eq0.16 EarningsMay 15 BMO Payout- Avg Volume2.82M Price3.01
Recom1.00 SMA2099.23% SMA50327.34% SMA200705.47% Volume154,518 Change1.01%
Oct-13-15Reiterated Chardan Capital Markets Buy $5 → $6.50
Oct-08-15Initiated ROTH Capital Buy $6
May-18-15Reiterated Chardan Capital Markets Buy $5 → $6
Mar-09-15Initiated Chardan Capital Markets Buy $5.50
Apr-24-17 08:41AM  Immune Pharma shares tumble 9% premarket as it unveils restructuring MarketWatch -20.96%
08:30AM  Immune Pharmaceuticals Announces Corporate Restructuring PR Newswire
08:15AM  Immune Receives Nasdaq Letter PR Newswire
Apr-21-17 07:30AM  Today's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Immune Pharmaceuticals Accesswire
Apr-20-17 10:25AM  Why Immune Pharmaceuticals Shares Are Skyrocketing 24/7 Wall St. +49.59%
09:07AM  Immune Pharma's stock rockets on heavy volume after license pact MarketWatch
08:00AM  Immune Pharmaceuticals Signs Letter of Intent with Pint Pharma Regarding License and Commercializion of Ceplene® in Latin America PR Newswire
Apr-12-17 07:30AM  Immune Pharmaceuticals Announces 1-for-20 Reverse Stock Split PR Newswire -5.48%
Mar-23-17 06:06AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
Mar-13-17 05:11PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Other Events
09:55AM  Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement PR Newswire
Feb-28-17 08:30AM  Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid PR Newswire -5.31%
Feb-17-17 09:15AM  Immune Pharmaceuticals Announces the launch of REMAIN , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia PR Newswire
Feb-15-17 04:30PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-06-17 08:15AM  Blog Coverage Pfizer Signs Agreement with Citibank to Repurchase $5 Billion Worth of Shares Accesswire
07:20AM  Purcell Julie & Lefkowitz LLP Is Investigating Immune Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Feb-03-17 05:29PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E -5.76%
Feb-01-17 04:03PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers +5.21%
Jan-27-17 07:00AM  Immune Pharmaceuticals Appoints New Chairman of the Board of Directors PR Newswire
Jan-23-17 08:45AM  Immune Pharmaceuticals Enters a Research Partnership to Develop Mono- and Bispecific Antibodies Against Novel Targets in the Tumor Microenvironment PR Newswire
Jan-19-17 04:02PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Other Events -6.13%
Jan-17-17 09:10AM  Immune Pharmaceuticals Satellite Symposium at the International Symposium on Acute Leukemias XVI PR Newswire
Jan-09-17 06:11PM  Immune Pharmaceuticals Will Request an Appeal to Regain Compliance with Nasdaq's Minimum Bid Price Rule PR Newswire
05:26PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Dec-22-16 04:51PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-20-16 04:09PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Dec-16-16 06:03AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Dec-02-16 04:05PM  Two Nano-Cap Pharma Stocks To Watch Right Now at Insider Monkey
Nov-26-16 01:04PM  IMMUNE PHARMACEUTICALS INC Financials
Nov-22-16 09:00AM  Immune Pharmaceuticals Announces Immuno-Oncology R&D Update on December 8, 2016 PR Newswire
06:02AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan
Nov-18-16 04:11PM  IMMUNE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -5.00%
Nov-17-16 09:15AM  Immune Pharmaceuticals Secures Up to $11 Million in New Financing to be Deployed With a Focus on Bertilimumab Clinical Development PR Newswire +5.26%
Nov-08-16 04:03PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Oct-28-16 11:20AM  Here Are Three Big Biotech Movers And Our Take On Whats Next at Insider Monkey -12.69%
Oct-27-16 07:00AM  Immune Pharmaceuticals Receives FDA Guidance for Phase III Pivotal Trial of its AML Therapy Ceplene® In Combination with Low Dose IL-2 PR Newswire +38.00%
Oct-17-16 09:23AM  Immune Pharmaceuticals Announces Formation of Management Team for Maxim Pharmaceuticals, its Pain and Neurology Subsidiary PR Newswire
Sep-16-16 07:58AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St -10.34%
07:30AM  Immune Pharmaceuticals Signs Agreement to Fund Maxim Pharmaceuticals, Inc., its Pain and Neurology subsidiary PR Newswire
Sep-07-16 07:33AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E +14.55%
07:30AM  Immune Pharmaceuticals Receives $2 Million Investment in Common Stock at $0.50 per Share PR Newswire
Aug-18-16 12:29PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Aug-16-16 07:30AM  Immune Pharmaceuticals Provides Business and R&D Update and Announces Second Quarter 2016 Financial Results PR Newswire
Aug-15-16 05:29PM  IMMUNE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Aug-05-16 02:15AM  Immune Pharmaceuticals Inc (IMNP) CEO Daniel Gedeon Teper Bought $356,250 of Stocks +15.15%
Aug-03-16 09:27AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
Jul-19-16 05:09PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Of -10.36%
09:30AM  IMMUNE Pharmaceuticals to Form Pain and Neurology Spin Off Company around AmiKet PR Newswire
Jul-06-16 05:26PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Jul-01-16 06:05AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jun-28-16 07:00AM  New Data Suggests Improved Tumor Response For The Combination of AZIXA® and Immune Checkpoint Inhibitors in The Treatment of Cancer PR Newswire +5.31%
Jun-21-16 09:00AM  Vista Partners Publishes June 2016 Macroeconomic & Investment Newsletter Marketwired +35.22%
Jun-20-16 05:30PM  New Data shows that Ceplene® Enhances Response to anti PD-1 and anti-PD-L1 Immune Checkpoint Inhibitors in Lymphoma and Solid Tumor Models PR Newswire
08:06AM  Immune Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016 PR Newswire
Jun-14-16 07:30AM  Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States PR Newswire
Jun-13-16 05:31PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
Jun-07-16 07:56PM  Immune Pharmaceuticals and Hadasit File a Joint Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies, Including Bertilimumab, for the Treatment of GI and Liver Diseases PR Newswire +9.06%
May-16-16 06:39PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +11.11%
05:57PM  IMMUNE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
07:30AM  Immune Pharmaceuticals Provides Business and R&D Update and Announces First Quarter 2016 Financial Results PR Newswire
May-05-16 09:00AM  Analyst Jason Napodano Discusses Immune Pharmaceuticals in Article for The Life Sciences Report Marketwired -5.00%
Apr-28-16 09:00AM  ROTH Capital Partners' Joseph Pantginis Interviewed by The Life Sciences Report Marketwired +7.50%
Apr-20-16 08:42AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
Apr-19-16 07:30AM  New Biomarker Data To Be Presented at AACR Helps Predict Overall Survival in Patients with Acute Myeloid Leukemia (AML) Treated with Ceplene® and Low-dose IL-2 Immunotherapy, Including Those Over 60 Years of Age PR Newswire +10.00%
Apr-18-16 10:25PM  IMNP: Phase 2 Clinical Trials of Bertilimumab Ongoing; Subsidiary to Develop Immunooncology Products.
Mar-31-16 04:10PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
Mar-30-16 06:41PM  Immune Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Full Year 2015 Financial Results PR Newswire -6.67%
06:10PM  IMMUNE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Mar-22-16 08:49AM  Keep Reading at noodls
07:30AM  Immune Pharmaceuticals Announces Publication of Preclinical Data in Support of Its Bispecific Antibody Platform in The Journal of Immunology PR Newswire
Mar-17-16 07:30AM  New Data on Ceplene® Cancer Immunotherapy to be Presented at the 2016 AACR Annual Meeting PR Newswire +11.63%
Feb-29-16 05:18PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers -10.87%
07:30AM  Immune Pharmaceuticals and The International Pemphigus & Pemphigoid Foundation (IPPF) Celebrate Rare Disease Day PR Newswire
Feb-25-16 07:30AM  Immune Pharmaceuticals Names Dr. Jeff Paley to its Board of Directors PR Newswire
Feb-24-16 07:30AM  Immune Pharmaceuticals Announces Publication of New Data on Eotaxin-1 in IBD; Patient Enrollment in Phase II UC Trial Continues PR Newswire
Feb-10-16 09:39AM  Immune Pharmaceuticals Files New Patent Application for Ceplene in Combination with Checkpoint Inhibitors PR Newswire +19.51%
Feb-08-16 04:39PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
07:30AM  Immune Pharmaceuticals to Present at 18th Annual BIO CEO & Investors Conference PR Newswire
Feb-04-16 04:13PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers -10.42%
Feb-03-16 07:30AM  Immune Pharmaceuticals Names John Neczesny to its Board of Directors PR Newswire -7.69%
Jan-15-16 04:46PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Jan-12-16 08:00AM  Immune Pharmaceuticals Announces 2016 Immuno-Oncology Plan PR Newswire +6.90%
Jan-11-16 04:31PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or -13.43%
Jan-07-16 04:02PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure,
Jan-04-16 08:00AM  Immune Pharmaceuticals Announces New Data with Topical Cyclosporine Nano-Capsules in Dermatology PR Newswire
Dec-31-15 04:34PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
Dec-28-15 08:00AM  Immune Pharmaceuticals Announces Exclusive License to a Novel Bispecific Antibody Technology PR Newswire
Dec-14-15 04:45PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or +6.06%
07:30AM  Immune Pharmaceuticals Announces New Data with Bi-Specific Antibody PR Newswire
Dec-10-15 01:20PM  What $40 or Less Oil Means to the Economy Marketwired
Dec-09-15 05:06PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a -6.76%
08:53AM  Immune Pharmaceuticals CEO Updates Shareholders On Company Progress PR Newswire
Dec-08-15 05:08PM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
Dec-07-15 07:30AM  G. John Mohr Joins Immune Pharmaceuticals as Senior Vice President of Business Development PR Newswire
Nov-19-15 07:30AM  Immune Pharmaceuticals Expands Leadership Team PR Newswire
Nov-17-15 12:15PM  IMNP: Clinical Sites to Open for BP Trial in the U.S. -9.71%
07:30AM  Immune Pharmaceuticals Announces Enrollment of the First Patient into the Phase 2 Clinical Trial with Bertilimumab in Ulcerative Colitis PR Newswire
Nov-16-15 05:58PM  IMMUNE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Nov-12-15 10:07AM  IMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -23.48%
07:30AM  Immune Pharmaceuticals Announces Third Quarter 2015 Corporate Update, Financial Results and Conference Call Details PR Newswire
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas. The company's lead product candidate is Bertilimumab, a human monoclonal antibody, which is in Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn's disease. It is also developing NanoCyclo, a topical nanocapsule formulation of cyclosporine, for the treatment of psoriasis and atopic dermatitis; Ceplene, a small molecule, which has completed Phase III clinical trials targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies; Azixa, a Phase II clinical trial novel microtubular destabilizer that functions as a vascular disruption agent; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer, which is in Phase II clinical trials for the treatment of patients with solid tumors. The company's products also include NanomAbs technology platform, an antibody-drug conjugate platform for the treatment of cancer; novel technology platform for the construction of bispecific antibodies for immunotherapies; and AmiKet, a prescription topical analgesic cream, which is in Phase III clinical trial to treat peripheral neuropathies. It has license, and other collaborative research and development arrangements with BioNanoSim Ltd.; Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.; Atlante Biotech SAS; Shire Biochem, Inc.; Lonza Sales AG; MabLife SAS; iCo Therapeutics Inc.; Dalhousie University; and Endo Pharmaceuticals Inc. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kazado DanielDirectorJan 04Buy0.1976,50314,2221,145,171Jan 04 05:09 PM
Kazado DanielDirectorDec 16Buy0.19161,37730,0001,068,667Dec 20 08:44 PM
Teper Daniel GedeonCEOOct 06Option Exercise0.04185,4737,4195,865,280Oct 11 06:10 PM
Kazado DanielDirectorAug 04Buy0.45666,667300,000907,290Aug 04 09:41 PM
Luchi Monica E.EVP & CMOAug 04Buy0.45777,778350,000777,778Aug 04 09:41 PM
Teper Daniel GedeonCEOAug 04Buy0.38937,500356,2505,748,405Aug 04 09:42 PM